What a talar osteochondral lesion actually is

If you have been told you have a cartilage problem in your ankle — often after months of pain that started with a sprain that never quite settled — you may be dealing with an osteochondral lesion of the talus, or OLT. Unlike a straightforward ligament injury, an OLT involves damage to both the smooth articular cartilage on the surface of the talar dome and the bone directly beneath it.

The talar dome is the rounded top of the ankle bone that bears your full bodyweight with every step. It carries a higher load per unit area than almost any other joint surface in the lower limb, and because cartilage here has a poor blood supply, it has very limited capacity to repair itself once injured.

Around 83% of talar osteochondral lesions occur on the medial (inner) side of the dome. Research published in 2025 links varus lower-limb alignment to medial lesions and valgus alignment to lateral ones, which is why overall limb mechanics matter alongside the focal defect itself. OLTs are most common in active adults between 20 and 40, and delayed diagnosis is frequent — symptoms can closely mimic those of a ligament sprain.

Why ankle cartilage defects rarely heal without intervention

Even with rest, physiotherapy, and anti-inflammatory medication, the ankle has limited ability to close a full-thickness cartilage gap on its own. Articular cartilage contains no blood vessels, which means the repair cells the body would normally dispatch through the bloodstream simply cannot reach the defect in meaningful numbers. What the joint produces instead — if anything — is fibrocartilage, a weaker, mechanically inferior tissue that tends to break down under the load the ankle carries daily.

Conservative care does have a role in early-stage cases. Activity modification, bracing, NSAIDs, and physiotherapy succeed in roughly 50% of acute, non-displaced lesions. For the other half — and for anyone with a chronic or displaced defect — waiting becomes a clinical liability rather than a strategy.

Lesion size sharpens that risk considerably. Data from Chuckpaiwong et al. shows that bone-marrow stimulation alone carries near-zero failure for defects below 15 mm in average diameter. At or above that threshold, the same approach succeeds in only approximately 3% of cases. Larger untreated defects tend to widen over time and can accelerate degeneration across the ankle joint — which is why clinicians take the size measurement seriously at the point of initial imaging.

How ChondroFiller works as an injectable collagen scaffold

ChondroFiller Liquid is a CE-marked Class III medical device — classified and regulated as an implant, not a drug, a painkiller, or a lubricant such as hyaluronic acid. The distinction matters: this is not an injection designed to mask symptoms in the short term.

The product is supplied in a two-chamber syringe. When the two chambers are combined at the point of delivery, collagen and a neutralising agent mix and begin to set. Placed into the ankle defect under ultrasound guidance — in an outpatient appointment, without surgical incision or general anaesthetic — the mixture gels into a porous, sponge-like hydrogel within approximately 3–5 minutes.

What follows is the reason the timeline is measured in months, not weeks. The scaffold does not itself become cartilage; instead it acts as a structural matrix that draws the body's own progenitor cells — recruited from the surrounding tissue and subchondral bone — to migrate in, differentiate, and begin laying down new tissue. This process is called acellular matrix-induced chondrogenesis: in plain terms, the scaffold creates the right physical and chemical environment for your own cells to do the repair work. Over 12–24 months, the collagen is gradually resorbed and replaced by hyaline-like tissue — closer in quality to native cartilage than the fibrocartilage produced by standard bone-marrow stimulation.

Some patients notice early symptomatic relief, but the underlying structural repair continues long after that. Most of the biological remodelling is still under way at six months, so the full benefit of the treatment takes time to emerge.

Which patients are suitable candidates

Suitability for ChondroFiller follows a clinical logic rather than a rigid checklist, but several factors shift the balance meaningfully.

Who tends to be a good fit

• Symptomatic adults — most often in the 20–40 active age group — with a full-thickness focal defect on the talar dome, typically up to approximately 12–15 mm in average diameter
• Patients who have completed a reasonable course of conservative management (activity modification, physiotherapy, NSAIDs, bracing) without adequate relief
• Those with focal rather than widespread cartilage loss — the scaffold is designed to fill a discrete defect, not to resurface a joint with generalised osteoarthritis
• Patients whose MRI confirms sufficient subchondral bone stock, so the scaffold has a stable base to settle against

Where it is generally not appropriate

• Diffuse ankle osteoarthritis affecting large areas of the joint surface
• Very large or cystic lesions where structural bone reconstruction is the primary need
• Lesion size significantly exceeding the 12–15 mm threshold, where a higher-tier surgical option is usually more appropriate

Limb alignment is also reviewed at assessment. Uncorrected varus or valgus loading concentrates force on one side of the talar dome and may undermine any focal repair over time.

Where pathology is mixed — for instance, a borderline-size defect alongside early lateral-compartment wear — a consultant assessment can identify whether ChondroFiller alone, combined treatment, or a different pathway offers the most durable result.

What the published evidence shows

The evidence base for ChondroFiller is worth understanding in its proper shape before looking at the numbers: most of the published data comes from knee populations. That context does not undermine the figures — outcomes have been consistent across joint types including the ankle — but it is the honest starting point for calibrating the results below.

Across published studies, 70–85% of patients achieve meaningful symptom relief at three to five years. The most methodologically substantial dataset is the Jerosch et al. post-market clinical follow-up (PMCF) study, in which mean IKDC scores improved by 32.4 points — well above the minimum clinically important difference of 16.7 points — with those gains sustained at three-year follow-up and patients reaching a mean functional score of 80.

MOCART imaging, which assesses structural repair quality on MRI, returned scores of 81.6–84.3 in European studies, indicating greater than 80% structural defect fill and good integration with surrounding native cartilage. Scores rose progressively from 65.3 at four weeks to 81.6 at twelve months, reflecting the scaffold's continued biological remodelling.

On safety and durability, the comparative picture is clear. Published reoperation rates for ChondroFiller run at approximately 3–8%, against up to 41% for microfracture and up to 37% for ACI/MACI, with complication rates near zero compared with up to 17% for ACI/MACI procedures.

The straightforward limitation: long-term randomised controlled trial data specifically in ankle populations remains limited, and such studies are ongoing. The ankle-specific evidence that exists is consistent with the broader dataset, but the talar OLT RCT evidence base is still developing. ChondroFiller is available at specialist private clinics in the UK and is not currently FDA-approved in the United States.

Booking an assessment at MSK Doctors

For patients who have a symptomatic, full-thickness focal defect on the talar dome, have not found adequate relief through conservative management, and fall within the lesion-size window where scaffold-based repair is appropriate — ChondroFiller represents a structured next step worth exploring with a specialist.

MSK Doctors is a CQC-registered, consultant-led group rated Good across all five inspection domains. Patients can self-refer directly — no GP letter required. The primary non-London sites for ChondroFiller assessment are Sleaford, Lincolnshire (home to the Regeneration Hub and an on-site Open MRI scanner) and Grantham, where the MFO Life Sciences Lab supports the group's regenerative medicine research. An initial appointment reviews current imaging, confirms defect size and suitability, and sets realistic expectations about the 12–24-month regeneration timeline.

For readers based in London, the same pathway is available through the London Cartilage Clinic, the group's London arm.

You can book an initial assessment online at mskdoctors.com — no referral needed.